Search research articles
Contact Us
Filters
Showing results (121-130 of 199) with videos related to
Page
of 20
Sort By:
Clinical Pharmacology and Therapeutics
|
March 1, 1977
Toward the operational identification of adverse drug reactions
F E Karch, L Lasagna
Communications in Psychopharmacology
|
January 1, 1978
Low plasma levels of CPZ in patients chronically treated with neuroleptics
R J Wyatt, L Lasagna
Clinical Pharmacology and Therapeutics
|
August 1, 1981
Estrogen patient package insert: medication acceptance despite negative attitudes
M Weintraub, S Glickstein, L Lasagna
Clinical Pharmacology and Therapeutics
|
September 1, 1983
Evaluation of current clinical trial methodology in analgesimetry based on experts' opinions and analysis of several analgesic studies
K Sriwatanakul, L Lasagna, C Cox
Clinical Pharmacology and Therapeutics
|
August 1, 1982
The quantification of pain: an analysis of words used to describe pain and analgesia in clinical trials
K Sriwatanakul, W Kelvie, L Lasagna
Clinical Pharmacology and Therapeutics
|
March 1, 1975
Commentary. The normal volunteer in clinical investigation: how rigid should selection criteria be?
P Joubert, L Rivera-Calimlim, L Lasagna
Clinical Pharmacology and Therapeutics
|
November 1, 1973
Effects of mode of management on plasma chlorpromazine in psychiatric patients
L Rivera-Calimlim, L Castañeda, L Lasagna
Journal of Clinical Pharmacology
|
January 1, 1978
Relationship of serum and myocardial digoxin concentration to electrocardiographic estimation of digoxin intoxication
T L Biddle, M Weintraub, L Lasagna
Journal of Clinical Pharmacology
|
August 1, 1989
Approvable letters in the FDA new drug approval process
B W Richard, M Ulcickas, L Lasagna
JAMA
|
April 23, 1973
Compliance as a determinant of serum digoxin concentration
M Weintraub, W Y Au, L Lasagna
Page
of 20
Search research articles
Search
Showing results (121-130 of 199) with videos related to
Sort By:
Page
of 20
Clinical Pharmacology and Therapeutics
|
March 1, 1977
Toward the operational identification of adverse drug reactions
F E Karch, L Lasagna
Communications in Psychopharmacology
|
January 1, 1978
Low plasma levels of CPZ in patients chronically treated with neuroleptics
R J Wyatt, L Lasagna
Clinical Pharmacology and Therapeutics
|
August 1, 1981
Estrogen patient package insert: medication acceptance despite negative attitudes
M Weintraub, S Glickstein, L Lasagna
Clinical Pharmacology and Therapeutics
|
September 1, 1983
Evaluation of current clinical trial methodology in analgesimetry based on experts' opinions and analysis of several analgesic studies
K Sriwatanakul, L Lasagna, C Cox
Clinical Pharmacology and Therapeutics
|
August 1, 1982
The quantification of pain: an analysis of words used to describe pain and analgesia in clinical trials
K Sriwatanakul, W Kelvie, L Lasagna
Clinical Pharmacology and Therapeutics
|
March 1, 1975
Commentary. The normal volunteer in clinical investigation: how rigid should selection criteria be?
P Joubert, L Rivera-Calimlim, L Lasagna
Clinical Pharmacology and Therapeutics
|
November 1, 1973
Effects of mode of management on plasma chlorpromazine in psychiatric patients
L Rivera-Calimlim, L Castañeda, L Lasagna
Journal of Clinical Pharmacology
|
January 1, 1978
Relationship of serum and myocardial digoxin concentration to electrocardiographic estimation of digoxin intoxication
T L Biddle, M Weintraub, L Lasagna
Journal of Clinical Pharmacology
|
August 1, 1989
Approvable letters in the FDA new drug approval process
B W Richard, M Ulcickas, L Lasagna
JAMA
|
April 23, 1973
Compliance as a determinant of serum digoxin concentration
M Weintraub, W Y Au, L Lasagna
Page
of 20